Last reviewed · How we verify
Tazarotene Cream, 0.1%
Tazarotene is a retinoid that binds to retinoid X receptors (RXR) and retinoid acid receptors (RAR) to regulate gene expression and reduce skin inflammation and abnormal keratinocyte differentiation.
Tazarotene is a retinoid that binds to retinoid X receptors (RXR) and retinoid acid receptors (RAR) to regulate gene expression and reduce skin inflammation and abnormal keratinocyte differentiation. Used for Plaque psoriasis, Acne vulgaris, Photoaging and photodamaged skin.
At a glance
| Generic name | Tazarotene Cream, 0.1% |
|---|---|
| Also known as | Tazorac® Cream, 0.1%, Tazorac Cream |
| Sponsor | Galderma R&D |
| Drug class | Retinoid |
| Target | Retinoid X Receptor (RXR), Retinoid Acid Receptor (RAR) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
As a third-generation retinoid, tazarotene selectively activates RXR and RAR nuclear receptors, which modulate transcription of genes involved in cell differentiation, proliferation, and inflammation. This leads to normalization of keratinization, reduced sebum production, and decreased inflammatory mediators in the skin. The drug is particularly effective in psoriasis and acne by promoting skin cell turnover and reducing hyperkeratinization.
Approved indications
- Plaque psoriasis
- Acne vulgaris
- Photoaging and photodamaged skin
Common side effects
- Skin irritation (erythema, burning, stinging)
- Peeling and desquamation
- Pruritus
- Photosensitivity
- Contact dermatitis
Key clinical trials
- Comparing the Efficacy of Topical Tazarotene Gel 0.1% v/s Microneedling in Atrophic Post Acne Scars (PHASE2, PHASE3)
- Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne (PHASE4)
- Efficacy of Tazarotene in Treatment of Verruca Plana (PHASE2)
- Dose Range Study of CD5789 in Acne Vulgaris (PHASE2)
- A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris (PHASE2)
- Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face (PHASE2)
- A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris (PHASE2)
- The Effect Of A Controlled Daily Skin Care Regimen On Retinoic Acid Tolerance (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |